<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157167</url>
  </required_header>
  <id_info>
    <org_study_id>NAV3-24</org_study_id>
    <secondary_id>1R44CA192859-01</secondary_id>
    <nct_id>NCT03157167</nct_id>
  </id_info>
  <brief_title>An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) Injection in Kaposi Sarcoma (KS)</brief_title>
  <official_title>An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navidea Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Navidea Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety of escalating doses of Tc 99m tilmanocept in HIV (human
      immunodeficiency virus) subjects with confirmed KS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-center, open-label, within-subject study of intravenously
      injected Tc 99m tilmanocept in the localization and detection of cutaneous and non-cutaneous
      KS tumor(s) in subjects with biopsy-confirmed KS. Six IV doses (Âµg/mCi) of tilmanocept will
      be evaluated in cohort groups.

      This study is designed to evaluate the safety and tolerability of escalating doses of Tc 99m
      tilmanocept. Whole body planar as well as 3D SPECT or SPECT/CT imaging will be performed to
      provide greater resolution of areas of Tc 99m tilmanocept localization.

      This study is designed to evaluate the use of Tc 99m tilmanocept as an imaging agent in
      HIV-positive subjects with known KS by evaluating the localization in known and unknown
      cutaneous and non-cutaneous lesions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single dose escalation study to determine safety</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Drug Reaction</measure>
    <time_frame>7 days after Tc 99m tilmanocept injection</time_frame>
    <description>Proportion of subjects experiencing noxious pharmacologic activity/an Adverse Drug Reaction (ADR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Per Subject Localization</measure>
    <time_frame>7 days after Tc 99m tilmanocept injection</time_frame>
    <description>Per subject localization rate of Tc 99m tilmanocept in at least one KS confirmed lesion by SPECT imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Localization concordance with physical observations</measure>
    <time_frame>7 days after Tc 99m tilmanocept injection</time_frame>
    <description>Per lesion concordance of Tc 99m localization with anatomical areas of active KS defined by confirmed diagnosis or clinical symptomology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Localization Intensity</measure>
    <time_frame>7 days after Tc 99m tilmanocept injection</time_frame>
    <description>Localization intensity for each clinically defined focus (as determined by quantitative SPECT gamma counts).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per subject localization</measure>
    <time_frame>7 days after Tc 99m tilmanocept injection</time_frame>
    <description>Per subject localization rate of Tc 99m tilmanocept in areas other than KS by SPECT and/or SPECT/CT imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per area localization rate</measure>
    <time_frame>7 days after Tc 99m tilmanocept injection</time_frame>
    <description>Per area localization rate of Tc 99m tilmanocept in the most frequently identified areas other than KS by SPECT and/or SPECT CT imaging.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Kaposi Sarcoma</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>100 mcg/5 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mcg/10 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mcg/5 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four subjects will receive a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mcg/10 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four subjects will receive a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mcg/5 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four subjects will receive a single IV injection of 400 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mcg/10 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four subjects will receive a single IV injection of 400 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tc99m-tilmanocept</intervention_name>
    <description>Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.</description>
    <arm_group_label>100 mcg/5 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_label>100 mcg/10 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_label>200 mcg/5 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_label>200 mcg/10 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_label>400 mcg/5 mCi Tc99m-Tilmanocept</arm_group_label>
    <arm_group_label>400 mcg/10 mCi Tc99m-Tilmanocept</arm_group_label>
    <other_name>Lymphoseek</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject has provided written informed consent with HIPAA authorization before the
             initiation of any study-related procedures.

          2. The subject is at least 18 years of age at the time of consent.

          3. The subject is HIV positive.

          4. The subject has a biopsy-confirmed diagnosis of KS and is classified into one of the
             categories below:

               1. Confirmed cutaneous KS/oral lesions without edema.

               2. Confirmed cutaneous KS/oral lesions with edema.

               3. Confirmed cutaneous KS/oral lesions with or without edema and suspected
                  non-cutaneous KS due to clinical symptomology or confirmed non-cutaneous KS
                  lesion(s).

        Exclusion Criteria:

          1. The subject is pregnant or lactating.

          2. The subject has received chemotherapy or radiation therapy to KS sites within one year
             of enrollment.

          3. The subject has known sensitivity to dextran.

          4. The subject has received an investigational product within 30 days prior to the Tc 99m
             tilmanocept administration.

          5. The subject has received any radiopharmaceutical within 7 days prior to the
             administration of Tc 99m tilmanocept.

          6. Any condition that, in the clinical judgment of the treating physician, is likely to
             prevent the subject from complying with any aspect of the protocol or that may put the
             subject at unacceptable risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Cope, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navidea Biopharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bonnie Abbruzzese</last_name>
    <phone>614-822-2327</phone>
    <email>babbruzzese@navidea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fred Cope, PhD</last_name>
    <phone>614-822-2320</phone>
    <email>fcope@navidea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toby A Maurer, MD</last_name>
      <email>maurert@derm.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Toby A Maurer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cope, F.O., W. Metz, et al. Innovations in receptor-targeted precision imaging at Navidea: diagnosis up close and personal. Nature Outlook (31 October 2013); S125-S129.</citation>
  </reference>
  <results_reference>
    <citation>Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Williams A, Schlesinger LS, Azad A, Rajaram MVS, Jarjour W, Young N, Rosol T, McGrath M. Corrigendum to the inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach [Nucl Med Biol 43 (2016) 215-225]. Nucl Med Biol. 2016 Dec;43(12):837. doi: 10.1016/j.nucmedbio.2016.10.001.</citation>
    <PMID>27866590</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kaposi Sarcoma, KS, HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

